Envelope Glycoprotein Determinants of Increased Entry in a Pathogenic Simian -Human Immunodeficiency Virus (SHIV-HXBc2P 3.2) Passaged in Monkeys

AIDS Research and Human Retroviruses

Volumn 20, Issue 2, 2004, Pages 163-173

  Si, Zhihai ^a   Gorry, Paul ^a   Babcock, Greg ^a   Owens, Christopher M ^a   Cayabyab, Mark ^a   Phan, Ngoc ^a   Sodroski, Joseph ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; MONKEY; MONONUCLEAR CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

ANIMALS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; RECEPTORS, CXCR4; RECOMBINANT FUSION PROTEINS; RECOMBINATION, GENETIC; RETROVIRIDAE PROTEINS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS; VIRULENCE; VIRUS REPLICATION;

EID: 1442274719     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922204773004888     Document Type: Review

References (63)

1. Barre-Sinoussi F, Chermann JC, Rey F, et al.: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871.
2. Gallo RC, Salahuddin SZ, Popovic M, et al.: Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500-503.
3. Clavel F, Guetard D, Brun-Vezinet F, et al.: Isolation of a new human retrovirus from West African patients with AIDS. Science 1986;233:343-346.
4. Desrosiers RC: The simian immunodeficiency viruses. Annu Rev Immunol 1990;8:557-578.
5. Fauci AS, Macher AM, Longo DL, et al.: NIH conference. Acquired immunodeficiency syndrome: Epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med 1984;100:92-106.
6. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
7. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
8. Hofmann W, Schubert D, LaBonte J, et al.: Species-specific, post-entry barriers to primate immunodeficiency virus infection. J Virol 1999;73:10020-10028.
9. Li J, Lord CI, Haseltine W, Letvin NL, and Sodroski J: Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr 1992;5:639-646.
10. Igarashi T, Shibata R, Hasebe F, et al.: Persistent infection with SIVmac chimeric virus having tat, rev, vpu, env and nef of HIV type 1 in macaque monkeys. AIDS Res Hum Retroviruses 1994;10:1021-1029.
11. Luciw PA, Pratt-Lowe E, Shaw KE, Levy JA, and Cheng-Mayer C: Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci USA 1995;92:7490-7494.
12. Reimann KA, Li JT, Voss G, et al.: An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol 1996;70:3198-3206.
13. Hayami M and Igarashi T: SIV/HIV-1 chimeric viruses having HIV-1 env gene: A new animal model and a candidate for attenuated live vaccine. Leukemia 1997;11(Suppl. 3):95-97.
14. Harouse JM, Gettie A, Tan RC, Blanchard J, and Cheng-Mayer C: Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 1999;284:816-819.
15. Endo Y, Igarashi T, Nishimura Y, et al.: Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus. J Virol 2000;74:6935-6945.
16. Chen Z, Zhao X, Huang Y, et al.: CD4+ lymphocytopenia in acute infection of Asian macaques by a vaginally transmissible subtype-C, CCR5-tropic simian/human immunodeficiency virus (SHIV). J Acquir Immune Defic Syndr 2002;30:133-145.
17. Reimann KA, Li JT, Veazey R, et al.: A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996;70:6922-6928.
18. Joag SV, Li Z, Foresman L, et al.: Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J Virol 1996;70:3189-3197.
19. Stephens EB, Joag SV, Sheffer D, et al.: Initial characterization of viral sequences from a SHIV-inoculated pig-tailed macaque that developed AIDS. J Med Primatol 1996;25:175-185.
20. Stephens EB, Mukherjee S, Sahni M, et al.: A cell-free stock of simian-human immunodeficiency virus that causes AIDS in pig-tailed macaques has a limited number of amino acid substitutions in both SIVmac and HIV-1 regions of the genome and has altered cytotropism. Virology 1997;231:313-321.
21. Cayabyab M, Karlsson GB, Etemad-Moghadam BA, et al.: Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2). J Virol 1999;73:976-984.
22. Karlsson GB, Halloran M, Li J, et al.: Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J Virol 1997;71:4218-4225.
23. Karlsson GB, Halloran M, Schenten D, et al.: The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques. J Exp Med 1998;188:1159-1171.
24. Sodroski J, Goh WC, Rosen C, Campbell K, and Haseltine WA: Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 1986;322:470-474.
25. Wyatt R and Sodroski J: The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998;280:1884-1888.
26. Allan JS, Coligan JE, Barin F, et al.: Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 1985;228:1091-1094.
27. Robey WG, Safai B, Oroszlan S, et al.: Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 1985;228:593-595.
28. Chan DC, Fass D, Berger JM, and Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-273.
29. Tan K, Liu J, Wang J, Shen S, and Lu M: Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci USA 1997;94:12303-12308.
30. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, and Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997;387:426-430.
31. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, and Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312:763-767.
32. Klatzmann D, Champagne E, Chamaret S, et al.: T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984;312:767-768.
33. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, and Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986;47:333-348.
34. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
35. Choe H, Farzan M, Sun Y, et al.: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
36. Deng H, Liu R, Ellmeier W, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
37. Doranz BJ, Rucker J, Yi Y, et al.: A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-1158.
38. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
39. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
40. Sattentau QJ, Moore JP, Vignaux F, Traincard F, and Poignard P: Conformational changes induced in the envelope glycoproteins of human and simian immunodeficiency viruses by soluble receptor binding. J Virol 1993;67:7383-7393.
41. Denisova G, Raviv D, Mondor I, Sattentau QJ, and Gershoni JM: Conformational transitions in CD4 due to complexation with HIV envelope glycoprotein gp120. J Immunol 1997;158:1157-1164.
42. Trkola A, Dragic T, Arthos J, et al.: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996;384:184-187.
43. Wu L, Gerard NP, Wyatt R, et al.: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996;384:179-183.
44. Rizzuto CD, Wyatt R, Hernandez-Ramos N, et al.: A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998;280:1949-1953.
45. LaBonte JA, Patel T, Hofmann W, and Sodroski J: Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells. J Virol 2000;74:10690-10698.
46. Joag SV, Li Z, Foresman L, et al.: Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques. AIDS Res Hum Retroviruses 1997;13:635-645.
47. Si Z, Cayabyab M, and Sodroski J: Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBC2P 3.2) derived by passage in monkeys. J Virol 2001;75:4208-4218.
48. Ye Y, Si ZH, Moore JP, and Sodroski J: Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo. J Virol 2000;74:11955-11962.
49. Thali M, Charles M, Furman C, et al.: Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J Virol 1994;68:674-680.
50. Babcock GJ, Mirzabekov T, Wojtowicz W, and Sodroski J: Ligand binding characteristics of CXCR4 incorporated into paramagnetic proteoliposomes. J Biol Chem 2001;276:38433-38440.
51. Basmaciogullari S, Babcock GJ, Van Ryk D, Wojtowicz W, and Sodroski J: Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding. J Virol 2002;76:10791-10800.
52. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, and Gregory TJ: Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990;265:10373-10382.
53. Freed EO and Martin MA: The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem 1995;270:23883-23886.
54. Korber B, Foley B, Kuiken C, Pillai S, and Sodroski J: Numbering positions in HIV relative to HXBc2. In: Human Retroviruses and AIDS 1998. Los Alamos National Laboratory, Los Alamos, NM, 1998.
55. Si Z, Phan N, Kiprilov E, and Sodroski J: Effects of HIV-1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res Hum Retrovirus 2003;19:217-226.
56. Hwang SS, Boyle TJ, Lyerly HK, and Cullen BR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991;253:71-74.
57. Henkel T, Westervelt P, and Ratner L: HIV-1 V3 envelope sequences required for macrophage infection. AIDS 1995;9:399-401.
58. Speck RF, Wehrly K, Platt EJ, et al.: Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 1997;71:7136-7139.
59. Hung CS, Vander Heyden N, and Ratner L: Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol 1999;73:8216-8226.
60. Lee WR, Yu XF, Syu WJ, Essex M, and Lee TH: Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41. J Virol 1992;66:1799-1803.
61. Etemad-Moghadam B, Rhone D, Steenbeke T, et al.: Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD4(+) T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J Virol 2001;75:5646-5655.
62. Etemad-Moghadam B, Sun Y, Nicholson EK, et al.: Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol 2000;74:4433-4440.
63. Yang X, Mahony E, Holm GH, Kassa A, and Sodroski J: Role of the gp120 inner domain β-sandwich in the interaction between the human immunodeficiency virus (HIV-1) envelope glycoprotein subunits. Virology 2003;313:117-125.